［1］MORTEZAEE K.Immune escape:A critical hallmark in solid tumors［J］.Life Sci,2020,258:118110.
［2］李洁琅,陈婷.PD-1/PD-L1抑制剂在晚期肝细胞肝癌治疗中的研究进展［J］.中国肿瘤临床,2020,47(5):265-268.
LI JL,CHEN T.Research progress of PD-1/PD-L1 inhibitors in the treatment of advanced hepatocellular carcinoma［J］.Chinese Journal of Clinical Oncology,2020,47(5):265-268.
［3］ZHAO R,CHINAI JM,BUHL S,et al.HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function［J］.Proc Natl Acad Sci USA,2013,110(24):9879-9884.
［4］ZHU Y,YAO S,ILIOPOULOU BP,et al.B7-H5 costimulates human T cells via CD28H［J］.Nat Commun,2013,4:2043.
［5］MULLER S,VICTORIA LAI W,ADUSUMILLI PS,et al.V-domain Ig-containing suppressor of T-cell activation(VISTA),a potentially targetable immune checkpoint molecule,is highly expressed in epithelioid malignant pleural mesothelioma［J］.Modern Pathology,2020,33(2):303-311.
［6］RIEDER SA,WANG J,WHITE N,et al.B7-H7(HHLA2)inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling［J］.Cell Mol Immunol,2021,18(6):1503-1511.
［7］JANAKIRAM M,CHINAI JM,FINEBERG S,et al.Expression,clinical significance,and receptor identification of the newest B7 family member HHLA2 protein［J］.Clin Cancer Res,2015,21(10):2359-2366.
［8］CRESPO J,VATAN L,MAJ T,et al.Phenotype and tissue distribution of CD28H(+)immune cell subsets［J］.Oncoimmunology,2017,6(12):e1362529.
［9］TIAN Y,SUN Y,GAO F,et al.CD28H expression identifies resident memory CD8+T cells with less cytotoxicity in human peripheral tissues and cancers［J］.Oncoimmunology,2018,8(2):e1538440.
［10］JANAKIRAM M,SHAH UA,LIU W,et al.The third group of the B7-CD28 immune checkpoint family:HHLA2,TMIGD2,B7x,and B7-H3［J］.Immunol Rev,2017,276(1):26-39.
［11］KOIRALA P,ROTH ME,GILL J,et al.HHLA2,a member of the B7 family,is expressed in human osteosarcoma and is associated with metastases and worse survival［J］.Scientific Reports,2016,6:31154.
［12］WANG Q,HE J,FLIES DB,et al.Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability［J］.Sci Rep,2017,7(1):6086.
［13］OSTROUMOV D,FEKETE-DRIMUSZ N,SABOROWSKI M,et al.CD4 and CD8 T lymphocyte interplay in controlling tumor growth［J］.Cell Mol Life Sci,2018,75(4):689-713.
［14］PALUSKIEVICZ CM,CAO X,ABDI R,et al.T Regulatory cells and priming the suppressive tumor microenvironment［J］.Front Immunol,2019,10:2453.
［15］HODGINS JJ,KHAN ST,PARK MM,et al.Killers 2.0:NK cell therapies at the forefront of cancer control［J］.J Clin Invest,2019,129(9):3499-3510.
［16］ZHUANG X,LONG EO.CD28 homolog is a strong activator of natural killer cells for lysis of B7H7(+)tumor cells［J］.Cancer Immunol Res,2019,7(6):939-951.
［17］BHATT RS,BERJIS A,KONGE JC,et al.KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1［J］.Cancer Immunol Res,2021,9(2):156-169.
［18］RAHIMI N,REZAZADEH K,MAHONEY JE,et al.Identification of IGPR-1 as a novel adhesion molecule involved in angiogenesis［J］.Mol Biol Cell,2012,23(9):1646-1656.
［19］WANG YHW,MEYER RD,BONDZIE PA,et al.IGPR-1 is required for endothelial cell-cell adhesion and barrier function［J］.J Mol Biol,2016,428(24 Pt B):5019-5033.
［20］WOOLF N,PEARSON BE,BONDZIE PA,et al.Targeting tumor multicellular aggregation through IGPR-1 inhibits colon cancer growth and improves chemotherapy［J］.Oncogenesis,2017,6(9):e378.
［21］SAKR MA,TAKINO T,DOMOTO T,et al.GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase［J］.Cancer Sci,2010,101(11):2368-2374.
［22］JANAKIRAM M,CHINAI JM,ZHAO A,et al.HHLA2 and TMIGD2:new immunotherapeutic targets of the B7 and CD28 families［J］.Oncoimmunology,2015,4(8):e1026534.
［23］XIAO Y,LI H,YANG LL,et al.The expression patterns and associated clinical parameters of human endogenous retrovirus-h long terminal repeat-associating protein 2 and transmembrane and immunoglobulin domain containing 2 in oral squamous cell carcinoma［J］.Dis Markers,2019,2019:5421985.
［24］LIN GB,YE HB,WANG JW,et al.Checkpoint human endogenous retrovirus-h long terminal repeat-associating protein 2 is upregulated and independently predicts unfavorable prognosis in bladder urothelial carcinoma［J］.Nephron,2019,141(4):256-264.
［25］KOIRALA P,ROTH ME,GILL J,et al.HHLA2,a member of the B7 family,is expressed in human osteosarcoma and is associated with metastases and worse survival［J］.Sci Rep,2016,6:31154.
［26］CHENG H,JANAKIRAM M,BORCZUK A,et al.HHLA2,a new immune checkpoint member of the B7 family,is widely expressed in human lung cancer and associated with EGFR mutational status［J］.Clin Cancer Res,2017,23(3):825-832.
［27］CHEN DM,CHEN W,XU Y,et al.Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma:a novel prognostic biomarker and potential therapeutic target［J］.Journal of Medical Genetics,2019,56(1):43-49.
［28］JING CY,FU YP,YI Y,et al.HHLA2 in intrahepatic cholangiocarcinoma:an immune checkpoint with prognostic significance and wider expression compared with PD-L1［J］.J Immunother Cancer,2019,7(1):77.
［29］ZHU Z,DONG W.Overexpression of HHLA2,a member of the B7 family,is associated with worse survival in human colorectal carcinoma［J］.Onco Targets Ther,2018,11:1563-1570.
［30］YAN H,QIU WL,DE GONZALEZ AKK,et al.HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival［J］.Cancer Letters,2019,442:333-340.
［31］QI YZ,DENG G,XU PF,et al.HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma［J］.Oncology Reports,2019,42(6):2309-2322.
［32］史圆圆,徐国才,张丙忠.免疫检查点HHLA2在上皮性卵巢癌中的表达及临床意义［J］.现代妇产科进展,2019,28(6):438-441.
SHI YY,XU GC,ZHANG BZ.Expression and clinical significance of HHLA2 in epithelial ovarian cancer［J］.Progress in Obstetrics and Gynecology,2019,28(6):438-441.
［33］HU C,XU Z,CHEN S,et al.Overexpression of B7H5/CD28H is associated with worse survival in human gastric cancer［J］.J Cell Mol Med,2020,24(2):1360-1369.
［34］SHIMONOSONO M,ARIGAMI T,YANAGITA S,et al.The association of human endogenous retrovirus-H long terminal repeat-associating protein 2(HHLA2)expression with gastric cancer prognosis［J］.Oncotarget,2018,9(31):22069-22078.
［35］TAI D,CHOO SP,CHEW V.Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers［J］.Cancers(Basel),2019,11(12):1926.
［36］罗详冲,李高峰.PD-1抑制剂卡瑞利珠单抗在晚期恶性肿瘤中的应用进展［J］.解放军医学杂志,2020,45(6):672-679.
LUO XC,LI GF.Application of PD-1 inhibitor camrelizumab in advanced malignancies［J］.Medical Journal of Chinese People's Liberation Army,2020,45(6):672-679.
［37］BAGCHI S,YUAN R,ENGLEMAN EG.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance［J］.Annu Rev Pathol,2021,16:223-249.
［38］陆舜,刘天舒.免疫检查点抑制剂相关不良事件的研究进展［J］.中国临床医学,2020,27(6):903-908.
LIU S,LIU TS.Research progress on adverse events related to immune checkpoint inhibitors［J］.Chinese Journal of Clinical Medicine,2020,27(6):903-908.
［39］周静文,何明基,练辉,等.免疫检查点抑制剂PD-1免疫相关不良反应的临床分析［J］.介入放射学杂志,2021,30(1):29-33.
ZHOU JW,HE MJ,LIAN H,et al.Clinical analysis of immune-related adverse events of PD-1 immune checkpoint［J］.Journal of Interventional Radiology,2021,30(1):29-33.